Literature DB >> 25514063

Complexity of illness and adjunctive benzodiazepine use in outpatients with bipolar I or II disorder: results from the Bipolar CHOICE study.

William V Bobo1, Noreen A Reilly-Harrington, Terence A Ketter, Benjamin D Brody, Gustavo Kinrys, David E Kemp, Richard C Shelton, Susan L McElroy, Louisa G Sylvia, James H Kocsis, Melvin G McInnis, Edward S Friedman, Vivek Singh, Mauricio Tohen, Charles L Bowden, Thilo Deckersbach, Joseph R Calabrese, Michael E Thase, Andrew A Nierenberg, Dustin J Rabideau, David A Schoenfeld, Stephen V Faraone, Masoud Kamali.   

Abstract

Benzodiazepines are widely prescribed for patients with bipolar disorders in clinical practice, but very little is known about the subtypes of patients with bipolar disorder or aspects of bipolar illness that contribute most to benzodiazepine use. We examined the prevalence of and factors associated with benzodiazepine use among 482 patients with bipolar I or II disorder enrolled in the Bipolar CHOICE study. Eighty-one subjects were prescribed benzodiazepines at study entry and were considered benzodiazepine users. Stepwise logistic regression was used to model baseline benzodiazepine use versus nonuse, using entry and exit criteria of P < 0.1. In bivariate analyses, benzodiazepine users were prescribed a significantly higher number of other psychotropic medications and were more likely to be prescribed lamotrigine or antidepressants as compared with benzodiazepine nonusers. Benzodiazepine users were more likely to have a diagnosis of bipolar I disorder and comorbid anxiety disorder, but not comorbid alcohol or substance use disorders. Benzodiazepine users also had experienced more anxiety and depressive symptoms and suicidality, but not irritability or manic symptoms, than did benzodiazepine nonusers. In the multivariate model, anxiety symptom level (regardless of diagnosis), lamotrigine use, number of concomitant psychotropic medications, college education, and high household income predicted benzodiazepine use. Benzodiazepine use in patients with bipolar disorders is associated with greater illness complexity as indicated by a higher number of concomitant psychotropic medications and higher anxiety symptom burden, regardless of a comorbid anxiety disorder diagnosis. Demographic factors were also important determinants of benzodiazepine use, which may be related to access to care and insurance coverage for benzodiazepines.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25514063      PMCID: PMC6557444          DOI: 10.1097/JCP.0000000000000257

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  30 in total

1.  Psychotropic drug prescription patterns among patients with bipolar I disorder.

Authors:  J Levine; K N Chengappa; J S Brar; S Gershon; E Yablonsky; D Stapf; D J Kupfer
Journal:  Bipolar Disord       Date:  2000-06       Impact factor: 6.744

Review 2.  The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues.

Authors:  Marlene P Freeman; Scott A Freeman; Susan L McElroy
Journal:  J Affect Disord       Date:  2002-02       Impact factor: 4.839

3.  Validity of the distinction between primary and secondary substance use disorder in patients with bipolar disorder: data from the first 1000 STEP-BD participants.

Authors:  Mark D Fossey; Michael W Otto; William R Yates; Steve R Wisniewski; Laszlo Gyulai; Michael H Allen; David J Miklowitz; Kim A Coon; Michael J Ostacher; Jackie L Neel; Michael E Thase; Gary S Sachs; Roger D Weiss
Journal:  Am J Addict       Date:  2006 Mar-Apr

4.  Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

Authors:  Naomi M Simon; Michael W Otto; Stephen R Wisniewski; Mark Fossey; Kemal Sagduyu; Ellen Frank; Gary S Sachs; Andrew A Nierenberg; Michael E Thase; Mark H Pollack
Journal:  Am J Psychiatry       Date:  2004-12       Impact factor: 18.112

5.  The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study.

Authors:  M A Frye; T A Ketter; G S Leverich; T Huggins; C Lantz; K D Denicoff; R M Post
Journal:  J Clin Psychiatry       Date:  2000-01       Impact factor: 4.384

Review 6.  New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon.

Authors:  Mario Giovanni Terzano; Mariano Rossi; Vincenzo Palomba; Arianna Smerieri; Liborio Parrino
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

7.  A controlled study of the effects of state surveillance on indicators of problematic and non-problematic benzodiazepine use in a Medicaid population.

Authors:  Dennis Ross-Degnan; Linda Simoni-Wastila; Jeffrey S Brown; Xiaoming Gao; Connie Mah; Leon E Cosler; Thomas Fanning; Peter Gallagher; Carl Salzman; Richard I Shader; Thomas S Inui; Stephen B Soumerai
Journal:  Int J Psychiatry Med       Date:  2004       Impact factor: 1.210

8.  Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders.

Authors:  Mary F Brunette; Douglas L Noordsy; Haiyi Xie; Robert E Drake
Journal:  Psychiatr Serv       Date:  2003-10       Impact factor: 3.084

9.  Benzodiazepine prescription practices and substance abuse in persons with severe mental illness.

Authors:  Robin E Clark; Haiyi Xie; Mary F Brunette
Journal:  J Clin Psychiatry       Date:  2004-02       Impact factor: 4.384

10.  Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD.

Authors:  Naomi M Simon; Michael W Otto; Roger D Weiss; Mark S Bauer; Sachiko Miyahara; Stephen R Wisniewski; Michael E Thase; Jane Kogan; Ellen Frank; Andrew A Nierenberg; Joseph R Calabrese; Gary S Sachs; Mark H Pollack
Journal:  J Clin Psychopharmacol       Date:  2004-10       Impact factor: 3.153

View more
  7 in total

1.  Treatment of Bipolar Depression with Deep TMS: Results from a Double-Blind, Randomized, Parallel Group, Sham-Controlled Clinical Trial.

Authors:  Diego F Tavares; Martin L Myczkowski; Rodrigo L Alberto; Leandro Valiengo; Rosa M Rios; Pedro Gordon; Bernardo de Sampaio-Junior; Izio Klein; Carlos G Mansur; Marco Antonio Marcolin; Beny Lafer; Ricardo A Moreno; Wagner Gattaz; Zafiris J Daskalakis; André R Brunoni
Journal:  Neuropsychopharmacology       Date:  2017-02-01       Impact factor: 7.853

2.  Center Predictors of Long-Term Benzodiazepine Use in Chronic Obstructive Pulmonary Disease and Post-traumatic Stress Disorder.

Authors:  Lucas M Donovan; Carol A Malte; Laura J Spece; Matthew F Griffith; Laura C Feemster; Steven B Zeliadt; David H Au; Eric J Hawkins
Journal:  Ann Am Thorac Soc       Date:  2019-09

3.  Hypnotic and Melatonin/Melatonin-Receptor Agonist Treatment in Bipolar Disorder: A Systematic Review and Meta-Analysis.

Authors:  Niall M McGowan; David S Kim; Marta de Andres Crespo; Lampros Bisdounis; Simon D Kyle; Kate E A Saunders
Journal:  CNS Drugs       Date:  2022-03-19       Impact factor: 5.749

4.  Bipolar Disorder and Polysubstance Use Disorder: Sociodemographic and Clinical Correlates.

Authors:  Andrea Aguglia; Antimo Natale; Laura Fusar-Poli; Andrea Amerio; Edoardo Bruno; Valeria Placenti; Eleonora Vai; Alessandra Costanza; Gianluca Serafini; Eugenio Aguglia; Mario Amore
Journal:  Front Psychiatry       Date:  2022-06-15       Impact factor: 5.435

5.  Preventive Medication Patterns in Bipolar Disorder and Their Relationship With Comorbid Substance Use Disorders in a Cross-National Observational Study.

Authors:  Romain Icick; Ingrid Melle; Bruno Etain; Margrethe Collier Høegh; Sébastien Gard; Sofie R Aminoff; Marion Leboyer; Ole A Andreassen; Raoul Belzeaux; Chantal Henry; Thomas D Bjella; Jean-Pierre Kahn; Nils Eiel Steen; Frank Bellivier; Trine Vik Lagerberg
Journal:  Front Psychiatry       Date:  2022-05-03       Impact factor: 5.435

6.  Real-world clinical features of and antidepressant prescribing patterns for outpatients with bipolar disorder.

Authors:  Keita Tokumitsu; Norio Yasui-Furukori; Naoto Adachi; Yukihisa Kubota; Yoichiro Watanabe; Kazuhira Miki; Takaharu Azekawa; Koji Edagawa; Eiichi Katsumoto; Seiji Hongo; Eiichiro Goto; Hitoshi Ueda; Masaki Kato; Reiji Yoshimura; Atsuo Nakagawa; Toshiaki Kikuchi; Takashi Tsuboi; Kazutaka Shimoda; Koichiro Watanabe
Journal:  BMC Psychiatry       Date:  2020-11-23       Impact factor: 3.630

7.  Patient educational level and management of bipolar disorder.

Authors:  Alina Karanti; Lana Bublik; Mathias Kardell; Kristina Annerbrink; Paul Lichtenstein; Bo Runeson; Erik Pålsson; Mikael Landén
Journal:  BJPsych Open       Date:  2021-03-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.